Recent progress and current challenges of immunotherapy in
advanced/metastatic esophagogastric adenocarcinoma

J 2022

Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma

MOEHLER, Markus, Anica HOEGNER, Anna D WAGNER, Radka OBERMANNOVÁ, Maria ALSINA et. al.

Základní údaje

Originální název

Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma

Autoři

MOEHLER, Markus (garant), Anica HOEGNER, Anna D WAGNER, Radka OBERMANNOVÁ (203 Česká republika, domácí), Maria ALSINA, Peter THUSS-PATIENCE, van Laarhoven HANNEKE a Elizabeth SMYTH

Vydání

European Journal of Cancer, Oxford, Elsevier Science Inc. 2022, 0959-8049

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 8.400

Kód RIV

RIV/00216224:14110/22:00128423

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.ejca.2022.08.023

UT WoS

000892112500002

Klíčová slova anglicky

Checkpoint inhibitors; Esophageal cancer; Esophagogastric cancer; Her2-positive; Immunotherapy; Gastric cancer; PD-L1; PD-1

Štítky

14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 31. 1. 2023 09:19, Mgr. Tereza Miškechová

Anotace

V originále

The new era of immunotherapy is successfully implemented in the treatment of metastatic/locally advanced esophagogastric adenocarcinoma (EGAC), as it has been investi-gated in combinations with/without chemotherapy in human epidermal growth factor receptor 2 (Her2)-positive and Her2-negative tumors. Recent approvals of immune checkpoint inhibi-tors (ICI) enrich the therapeutic landscape in nearly every therapeutic line. Based on CHECKMATE-649, the combination of nivolumab and chemotherapy in first-line therapy of programmed cell death protein 1 (PD-L1)-positive patients with advanced gastroesophageal junction cancer (GEJC), esophageal cancer (EC), and gastric cancer (GC) was approved in Europe for PD-L1 combined positivity score (CPS) >= 5 patients and independently from PD-L1 score in the USA and Asia. Based on KEYNOTE-590, patients with advanced GEJC and EC qualify for the combination of pembrolizumab plus chemotherapy in Europe (CPS > 10) and the USA. For Her2-positive patients, trastuzumab with first-line chemo-therapy plus pembrolizumab has beneficial response rates and resulted in approval in the USA (KEYNOTE-811). In third-line therapy, superior overall survival (OS) was achieved by the administration of nivolumab (approval in Japan, ATTRACTION-02), and pembroli-zumab shows a positive effect on the duration of response (KEYNOTE-059). Questions of resistance to immunotherapy or the role of gender in response to ICI need to be clarified. This review provides an overview of the current approvals of ICI in advanced EGAC and reflects results of relevant phase II/III trials with focus on possible biomarkers, including PD-L1 CPS and microsatellite-instability (MSI) status.

Citovat

MOEHLER, Markus, Anica HOEGNER, Anna D WAGNER, Radka OBERMANNOVÁ, Maria ALSINA, Peter THUSS-PATIENCE, van Laarhoven HANNEKE a Elizabeth SMYTH. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma. European Journal of Cancer. Oxford: Elsevier Science Inc., 2022, roč. 176, November 2022, s. 13-29. ISSN 0959-8049. Dostupné z: https://dx.doi.org/10.1016/j.ejca.2022.08.023.

@article{2251362,
   author = {Moehler, Markus and Hoegner, Anica and Wagner, Anna D and Obermannová, Radka and Alsina, Maria and ThussandPatience, Peter and Hanneke, van Laarhoven and Smyth, Elizabeth},
   article_location = {Oxford},
   article_number = {November 2022},
   doi = {http://dx.doi.org/10.1016/j.ejca.2022.08.023},
   keywords = {Checkpoint inhibitors; Esophageal cancer; Esophagogastric cancer; Her2-positive; Immunotherapy; Gastric cancer; PD-L1; PD-1},
   language = {eng},
   issn = {0959-8049},
   journal = {European Journal of Cancer},
   title = {Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma},
   url = {https://www.sciencedirect.com/science/article/pii/S095980492200510X?via%3Dihub},
   volume = {176},
   year = {2022}
}

TY  - JOUR
ID  - 2251362
AU  - Moehler, Markus - Hoegner, Anica - Wagner, Anna D - Obermannová, Radka - Alsina, Maria - Thuss-Patience, Peter - Hanneke, van Laarhoven - Smyth, Elizabeth
PY  - 2022
TI  - Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma
JF  - European Journal of Cancer
VL  - 176
IS  - November 2022
SP  - 13-29
EP  - 13-29
PB  - Elsevier Science Inc.
SN  - 09598049
KW  - Checkpoint inhibitors
KW  - Esophageal cancer
KW  - Esophagogastric cancer
KW  - Her2-positive
KW  - Immunotherapy
KW  - Gastric cancer
KW  - PD-L1
KW  - PD-1
UR  - https://www.sciencedirect.com/science/article/pii/S095980492200510X?via%3Dihub
N2  - The new era of immunotherapy is successfully implemented in the treatment of metastatic/locally advanced esophagogastric adenocarcinoma (EGAC), as it has been investi-gated in combinations with/without chemotherapy in human epidermal growth factor receptor 2 (Her2)-positive and Her2-negative tumors. Recent approvals of immune checkpoint inhibi-tors (ICI) enrich the therapeutic landscape in nearly every therapeutic line. Based on CHECKMATE-649, the combination of nivolumab and chemotherapy in first-line therapy of programmed cell death protein 1 (PD-L1)-positive patients with advanced gastroesophageal junction cancer (GEJC), esophageal cancer (EC), and gastric cancer (GC) was approved in Europe for PD-L1 combined positivity score (CPS) >= 5 patients and independently from PD-L1 score in the USA and Asia. Based on KEYNOTE-590, patients with advanced GEJC and EC qualify for the combination of pembrolizumab plus chemotherapy in Europe (CPS > 10) and the USA. For Her2-positive patients, trastuzumab with first-line chemo-therapy plus pembrolizumab has beneficial response rates and resulted in approval in the USA (KEYNOTE-811). In third-line therapy, superior overall survival (OS) was achieved by the administration of nivolumab (approval in Japan, ATTRACTION-02), and pembroli-zumab shows a positive effect on the duration of response (KEYNOTE-059). Questions of resistance to immunotherapy or the role of gender in response to ICI need to be clarified. This review provides an overview of the current approvals of ICI in advanced EGAC and reflects results of relevant phase II/III trials with focus on possible biomarkers, including PD-L1 CPS and microsatellite-instability (MSI) status.
ER  -

MOEHLER, Markus, Anica HOEGNER, Anna D WAGNER, Radka OBERMANNOVÁ, Maria ALSINA, Peter THUSS-PATIENCE, van Laarhoven HANNEKE a Elizabeth SMYTH. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma. \textit{European Journal of Cancer}. Oxford: Elsevier Science Inc., 2022, roč.~176, November 2022, s.~13-29. ISSN~0959-8049. Dostupné z: https://dx.doi.org/10.1016/j.ejca.2022.08.023.

Podrobný výpis o publikaci